Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Giovanna P. Colletti Giovanna (Joanne) Picardo Colletti, 82, of 41 Sanford Drive Jamestown, passed away unexpectedly on May 30, 2025, at her home. She was born on March 12, 1943, in Marianopoli, ...

Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of intellectual property rights ...

Is Vertex stock a buy? Vertex's share price is still in positive territory year to date despite today's pullback.

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...

Giovanna Flores’s fall collection began in an unlikely place—with mops. “I’ve worked with rope before and I’ve always thought these mops were pretty, so I was playing around with them on ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).

Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx, is the first such treatment to hit the ...